Allied-Bristol Life Sciences Licenses Technology and Molecules from Yale
August 27 2015 - 4:45AM
Dow Jones News
LONDON--Allied-Bristol Life Sciences, LLC, a biopharmaceutical
enterprise jointly owned between Allied Minds (ALM.LN) and
Bristol-Myers Squibb Company (BMY), on Thursday announced that it
has entered into a worldwide licensing agreement with Yale
University for a platform technology and associated lead molecules
that will be further developed to treat diseases such as prostate
cancer.
Allied Minds shares at 0813 GMT up 20 pence, or 4.65%, at 450
pence.
-Write to Jana Simmons at jana.simmons@wsj.com
Subscribe to WSJ: http://online.wsj.com?mod=djnwires
(END) Dow Jones Newswires
August 27, 2015 04:30 ET (08:30 GMT)
Copyright (c) 2015 Dow Jones & Company, Inc.
Allied Minds (LSE:ALM)
Historical Stock Chart
From Aug 2024 to Sep 2024
Allied Minds (LSE:ALM)
Historical Stock Chart
From Sep 2023 to Sep 2024